387 related articles for article (PubMed ID: 28669340)
1. Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.
Zhang T; Kordish DH; Suryawanshi YR; Eversole RR; Kohler S; Mackenzie CD; Essani K
Curr Cancer Drug Targets; 2018; 18(6):577-591. PubMed ID: 28669340
[TBL] [Abstract][Full Text] [Related]
2. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
[TBL] [Abstract][Full Text] [Related]
3. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
Zhang T; Essani K
Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
[TBL] [Abstract][Full Text] [Related]
4. Tanapoxvirus: From discovery towards oncolytic immunovirotherapy.
Suryawanshi YR; Zhang T; Razi F; Essani K
J Cancer Res Ther; 2020; 16(4):708-712. PubMed ID: 32930107
[TBL] [Abstract][Full Text] [Related]
5. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
[TBL] [Abstract][Full Text] [Related]
6. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.
Zhang T; Suryawanshi YR; Kordish DH; Woyczesczyk HM; Jeng D; Essani K
Virus Genes; 2017 Feb; 53(1):52-62. PubMed ID: 27738905
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.
Conrad SJ; El-Aswad M; Kurban E; Jeng D; Tripp BC; Nutting C; Eversole R; Mackenzie C; Essani K
J Exp Clin Cancer Res; 2015 Feb; 34(1):19. PubMed ID: 25887490
[TBL] [Abstract][Full Text] [Related]
8. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model.
El-Shemi AG; Ashshi AM; Na Y; Li Y; Basalamah M; Al-Allaf FA; Oh E; Jung BK; Yun CO
J Exp Clin Cancer Res; 2016 May; 35():74. PubMed ID: 27154307
[TBL] [Abstract][Full Text] [Related]
10. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
11. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Zamarin D; Vigil A; Kelly K; García-Sastre A; Fong Y
Gene Ther; 2009 Jun; 16(6):796-804. PubMed ID: 19242529
[TBL] [Abstract][Full Text] [Related]
13. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
[TBL] [Abstract][Full Text] [Related]
15. Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia.
Wang W; Liu S; Dai P; Yang N; Wang Y; Giese RA; Merghoub T; Wolchok J; Deng L
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34593618
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice.
Vähä-Koskela MJ; Kallio JP; Jansson LC; Heikkilä JE; Zakhartchenko VA; Kallajoki MA; Kähäri VM; Hinkkanen AE
Cancer Res; 2006 Jul; 66(14):7185-94. PubMed ID: 16849565
[TBL] [Abstract][Full Text] [Related]
17. The construction of a new oncolytic herpes simplex virus expressing murine interleukin-15 with gene-editing technology.
Cai L; Hu H; Duan H; Li Y; Zou Z; Luo K; Zhang Z; Yang J; Jin J; Chen Y; Ke Z; Fang Z; Liu Q; Hong X; Hu S; Liu B
J Med Virol; 2020 Dec; 92(12):3617-3627. PubMed ID: 31994741
[TBL] [Abstract][Full Text] [Related]
18. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.
Zheng JN; Pei DS; Mao LJ; Liu XY; Sun FH; Zhang BF; Liu YQ; Liu JJ; Li W; Han D
Cancer Gene Ther; 2010 Jan; 17(1):28-36. PubMed ID: 19498459
[TBL] [Abstract][Full Text] [Related]
20. Enhanced IL-12 transgene expression improves oncolytic viroimmunotherapy.
Kim Y; Saini U; Kim D; Hernandez-Aguirre I; Hedberg J; Martin A; Mo X; Cripe TP; Markert J; Cassady KA; Dhital R
Front Immunol; 2024; 15():1375413. PubMed ID: 38895115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
